Saprami

Saprami is a clinical-stage biotechnology company focused on developing innovative treatments for chronic kidney disease (CKD) and related cardiovascular conditions. The company's lead program, SPRM-210, is a highly selective, non-steroidal mineralocorticoid receptor antagonist (ns-MRA) designed to provide the cardiorenal benefits of MR inhibition while minimizing the risk of hyperkalemia. Founded by industry veterans with extensive experience in renal and cardiovascular drug development, Saprami aims to address significant unmet needs in the management of progressive kidney disease. The company leverages its expertise in ns-MRA chemistry to create therapies that offer superior safety and efficacy profiles compared to traditional steroidal treatments.